Hair loss has always been an emotional concern, especially for young men dealing with early thinning and receding hairlines. From minoxidil to finasteride, people are constantly searching for safer and more effective solutions. Clascoterone is the new buzzword in the hair restoration field. It is still under trial, but it has shown effective results in male pattern hair loss, also known as androgenetic alopecia.

Clascoterone (also known as Breezula) is a topical medication originally FDA-approved for acne at 1% (under the brand name Winlevi) and has now been developed specifically for hair loss. Social media discussions and online forums are already calling it a potential “game-changer” and even a non-surgical alternative to hair transplant. Naturally, this has led to rising curiosity, with many asking:

• Is it really a breakthrough?
• Or is it just another hyped product?
• When will clascoterone be available in India?

In this blog, we break down the available clinical evidence, safety data, mechanism of action, comparison with current hair loss treatments, and the future potential of clascoterone.

What Is Clascoterone 5% Solution?

Clascoterone is a novel topical anti-androgen that targets and blocks dihydrotestosterone (DHT) locally in the scalp. The solution works by slowing follicular miniaturisation and boosting hair regrowth, with low systemic hormonal impact observed in early trial data.

The 5% solution is under Phase III clinical trials (SCALP-1 and SCALP-2) to study its effectiveness for male pattern hair loss. However, regulatory approvals for hair loss use are still pending in many countries. For now, based on the trial protocols, the solution would be used as follows once available:

• Application: Spread the 5% topical solution on the affected areas of the scalp
• Frequency: Apply twice daily (morning and evening)
• Dosage: As prescribed by your dermatologist
• Who should use it: Studied for male and female pattern baldness, and may suit people who are cautious about oral finasteride due to possible side effects

How Does Clascoterone Work for Hair Loss? (Mechanism)

Clascoterone 5% for male pattern hair loss is specifically designed for patients dealing with androgenetic alopecia. Unlike oral medications that reduce DHT levels throughout the body, clascoterone is designed to act locally on the scalp. It works by blocking androgen (DHT) receptors in the scalp, targeting the hormonal trigger of pattern baldness without major systemic hormone changes.

Clinical Trials: Current Status and Expectations

Clascoterone 5% solution for androgenetic alopecia (male pattern hair loss) is currently being evaluated in Phase III clinical trials under the name Cortexolone 17alpha-propionate (CB-03-01).

What the Phase III Trials Include

The Phase III programme for clascoterone, announced in June 2023, includes approximately 1,400 to 1,500 men aged 18 and over, enrolled across nearly 60 clinical centres in the US and Europe. The studies are designed in two parts to evaluate both effectiveness and safety:

• Part 1: 6-month double-blind phase studying Target Area Hair Count (TAHC)
• Part 2: 6-month single-blind extension studying Patient-Reported Outcomes (PROs)

As per trial updates and current status, the study is completing its mandatory 12-month safety evaluation, with the final safety follow-up expected through Spring 2026.

Expected Results

According to published Phase III findings (SCALP 1 and SCALP 2) so far, the trials demonstrated significant improvements in hair growth and positive patient-reported outcomes:

• Statistically significant improvement in Target Area Hair Count versus placebo
• Up to 539% relative improvement in one trial
• 168% relative improvement in the second trial
• Positive Patient-Reported Outcomes supporting visible improvement
• Favourable safety profile, with mainly mild scalp irritation

If regulatory approval is granted, clascoterone may be positioned as a first-line topical therapy for male pattern hair loss, offering a new mechanism of action that targets DHT.

Is Clascoterone Safe? Side Effects and Long-Term Risks

Safety is one of the most important considerations with any new hair loss treatment. In Phase III clinical trials, clascoterone 5% solution for androgenetic alopecia was generally safe and well accepted by most participants. Most reported side effects were local and mild, including:

• Scalp redness
• Mild itching
• Irritation at the application site

So far, clinical trials have not shown a significant increase in systemic hormonal side effects compared with placebo.

Current Limitations

Even where clascoterone is available for other indications, its use for hair loss remains under regulatory review in many regions. Based on current labelling and trial populations, it has not been approved or recommended for the following groups:

• Pregnancy
• Breastfeeding women
• Children under 18 years
• Adults 65 years and above

Long-Term Risks (Under Review)

The Phase III programme includes a full 12-month follow-up (double-blind phase plus extension), which is specifically meant to track:

• Ongoing scalp tolerability
• Any delayed side effects
• Overall safety with continued use

Until the full safety review is completed and regulators confirm the indication, clascoterone should be considered an emerging therapy and used only under appropriate medical guidance where it is legally approved.

Clascoterone vs Other Hair Loss Treatments

When comparing clascoterone for hair loss in India with existing therapies, it is important to understand that each treatment works through a different mechanism.

For a detailed head-to-head, read our full comparison of clascoterone vs finasteride, and our overview of minoxidil vs DHT blockers to understand how growth stimulation and DHT control differ.

Can Clascoterone Replace a Hair Transplant?

A hair transplant is a surgical procedure that redistributes safe donor hair to thinning or bald areas. It physically restores density in areas where follicles are no longer active.

Clascoterone, a medicine for hair regrowth, may help slow thinning and improve density in early-stage hair loss. However, it cannot regrow hair in completely bald areas where follicles are inactive. In advanced male pattern baldness, surgical restoration remains the only option to rebuild density.

When Will Clascoterone Be Available in India?

At present, clascoterone 5% for male pattern hair loss is not approved in India for androgenetic alopecia and is not available over the counter.

The drug is currently completing its mandatory 12-month safety follow-up in Phase III trials. Based on trial timelines and regulatory review processes, approval decisions in major markets are expected around Spring 2026. Availability in India would follow a separate regulatory review thereafter.

Is Clascoterone the Ultimate Game-Changer?

Clascoterone is being discussed as a “game-changer” because it represents a new mechanism for male pattern hair loss after nearly 30 years, beyond the usual minoxidil (growth stimulation) and finasteride (systemic DHT reduction). People have already started searching for “clascoterone for hair loss results” because the data is stronger than what we usually see at the early development stage of hair loss drugs.

Most large-scale trials have focused on hair loss in men, but the mechanism may also be relevant to female pattern hair loss, where androgen sensitivity plays a role. Clinical data on women remain limited.

However, experts describe it as promising, not revolutionary yet. It works best in the early to moderate stages (Stages 2 to 3), when follicles are still active. It does not replace a hair transplant in advanced baldness, where follicles are permanently inactive. Its future potential depends on long-term safety data, regulatory approval, real-world results, and how it performs in combination therapies.

Frequently Asked Questions